DS-8273a clinical trials
Also written DS-8273a.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses DS-8273a is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DS-8273a
- 2
Studies by the year they started
3 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Studies
Open first, then newest update. How each study uses DS-8273a is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaCompletedPhase 1NYU Langone HealthNCT02983006Written as DS-8273aHow we know
- Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or LymphomasCompletedPhase 1Daiichi SankyoNCT02076451Written as DS-8273aHow we know
- Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal CancerTerminatedPhase 1Daiichi SankyoNCT02991196Written as DS-8273a + nivolumabHow we know
Codes
What other systems call DS-8273a · ClinicalTrials.gg INT000909
- MeSH (NLM) C000626597DS-8273aOne source ClinicalTrials.gov
- UNII (FDA) G674PEN33TDS-8273AOne source FDA
- NCI Thesaurus C121158Anti-DR5 Agonistic Antibody DS-8273aOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626597 | DS-8273a | One source ClinicalTrials.gov |
| UNII (FDA) | G674PEN33T | DS-8273A | One source FDA |
| NCI Thesaurus | C121158 | Anti-DR5 Agonistic Antibody DS-8273a | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.